Acurx PharmaceuticalsACXP
About: Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
Employees: 4
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0.23% less ownership
Funds ownership: 7.91% [Q2] → 7.68% (-0.23%) [Q3]
16% less capital invested
Capital invested by funds: $2.81M [Q2] → $2.37M (-$441K) [Q3]
16% less funds holding
Funds holding: 25 [Q2] → 21 (-4) [Q3]
32% less call options, than puts
Call options by funds: $17K | Put options by funds: $25K
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Ed Arce 54% 1-year accuracy 59 / 109 met price target | 745%upside $12 | Buy Reiterated | 14 Nov 2024 |
Financial journalist opinion
Based on 6 articles about ACXP published over the past 30 days
